Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1

American Journal of Respiratory Cell and Molecular Biology

Volumn 37, Issue 4, 2007, Pages 438-446

  Hoshino, Yuma ^a,c   Nakamura, Takayuki ^a   Sato, Atsuyasu ^b   Mishima, Michiaki ^b   Yodoi, Junji ^b   Nakamura, Hajime ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Antioxidants; Chronic obstructive pulmonary disease; Cytoprotection; Therapeutics

Indexed keywords

CATALASE; CIGARETTE SMOKE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; NEUROTROPIN; OXIDIZING AGENT; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROTECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG DISEASE; LUNG INJURY; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANALGESICS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CYTOPROTECTION; HUMANS; LUNG; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; POLYSACCHARIDES; RABBITS; THIOREDOXIN;

HUMAN HERPESVIRUS 4; HUMAN T-LYMPHOTROPIC VIRUS 1; MUS; ORYCTOLAGUS CUNICULUS; VACCINIA VIRUS;

EID: 34848826329     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2006-0402OC     Document Type: Article

References (47)

1. Petty TL, Weinmann GG. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute Workshop Summary. Bethesda, MD, August 29-31, 1995. JAMA 1997;277:246-253.
2. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26:835-845.
3. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
4. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320: 1297-1303.
5. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-982.
6. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-571.
7. Rennard SI, Schachter N, Strek M, Rickard K, Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66.
8. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1552-1560.
9. Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T, Yamaoka Y, Ozawa K, Yodoi J. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 1994;42:75-80.
10. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 1997;15:351-369.
11. Jikimoto T, Nishikubo Y, Koshiba M, Kanagawa S, Morinobu S, Morinobu A, Saura R, Mizuno K, Kondo S, Toyokuni S, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 2002;38:765-772.
12. Callister ME, Burke-Gaffney A, Quinlan GJ, Nicholson AG, Florio R, Nakamura H, Yodoi J, Evans TW. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax 2006;61:521-527.
13. Yamada Y, Nakamura H, Adachi T, Sannohe S, Oyamada H, Kayaba H, Yodoi J, Chihara J. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol Lett 2003;86:199-205.
14. Miwa K, Kishimoto C, Nakamura H, Makita T, Ishii K, Okuda N, Yodoi J, Sasayama S. Serum thioredoxin and α-tocopherol concentrations in patients with major risk factors. Circ J 2005;69:291-294.
15. Nakamura H, Tamura S, Watanabe I, Iwasaki T, Yodoi J. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol Lett 2002;82:165-170.
16. Ueda S, Nakamura T, Yamada A, Teratani A, Matsui N, Furukawa S, Hoshino Y, Narita M, Yodoi J, Nakamura H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci 2006;79:1170-1177.
17. Ohashi S, Nishio A, Nakamura H, Kido M, Ueno S, Uza N, Inoue S, Kitamura H, Kiriya K, Asada M, et al. Protective roles of redox-active protein thioredoxin-1 for severe acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2006;290:G772-G781.
18. Liu W, Nakamura H, Shioji K, Tanito M, Oka S, Ahsan MK, Son A, Ishii Y, Kishimoto C, Yodoi J. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 2004;110:1276-1283.
19. Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, Fukuda K, Yodoi J. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytcs. Biochem Biophys Res Commun 2000;275:825-830.
20. Yuan Z, Kishimoto C, Shioji K, Nakamura H, Yodoi J, Sasayama S. Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Cardiovasc Res 2002;55:320-328.
21. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci 2005;46:979-987.
22. Ohara H, Namimatsu A, Fukuhara K, Yago H, Yoneda R, Saito K, Inoki R. Release of inflammatory mediators by noxious stimuli; effect of neurotropin on the release. Eur J Pharmacol 1988;157:93-99.
23. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, Tursz T. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 1990;87:8282-8286.
24. Hoshino Y, Mio T, Nagai S, Miki H, Ito I, Izumi T. Cytotoxic effects of cigarette smoke extract on an alveolar type II cell-derived cell line. Am J Physiol Lung Cell Mol Physiol 2001;281:L509-L516.
25. Tanito M, Masutani H, Nakamura H, Ohira A, Yodoi J. Cytoprotective effect of thioredoxin against retinal photic injury in mice. Invest Ophthalmol Vis Sci 2002;43:1162-1167.
26. De S, Rosen J, Dagan A, Swanson P, Sinanan M, Hannaford B. Assessment of tissue damage due to mechanical stresses. In: Biomedical Robotics and Biomechatronics, 2006. The First IEEE/RAS-EMBS International Conference, Pisa, Italy, 2006; pp. 823-828.
27. Hata T, Kita T, Itoh E, Oyama R, Kawabata A. Mechanism of the analgesic effect of neurotropin. Jpn J Pharmacol 1988;48:165-173.
28. Namimatsu A, Go K, Hata T. Regulatory effect of neurotropin on nasal mucosal hypersensitivity in Guinea pigs caused by SART (intermittent exposure to cold) stress. Jpn J Pharmacol 1992;59:371-377.
29. Yoshii H, Fukata Y, Yamamoto K, Naiki M, Suehiro S, Yanagihara Y, Okudaira H. Neurotropin inhibits accumulation of eosinophils induced by allergen through the suppression of sensitized T-cells. Int J Immunopharmacol 1995;17:879-886.
30. Kaimul Ahsan M, Nakamura H, Tanito M, Yamada K, Utsumi H, Yodoi J. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med 2005;39:1549-1559.
31. Gon Y, Sasada T, Matsui M, Hashimoto S, Takagi Y, Iwata S, Wada H, Horie T, Yodoi J. Expression of thioredoxin in bleomycin-injured airway epithelium: possible role of protection against bleomycin induced epithelial injury. Life Sci 2001;68:1877-1888.
32. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-2606.
33. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006;533:222-239.
34. Billiet L, Furman C, Larigauderie G, Copin C, Brand K, Fruchart JC, Rouis M. Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1β expression in human monocyte-derived macrophages. J Biol Chem 2005;280:40310-40318.
35. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004;110:856-861.
36. Soini Y, Kahlos K, Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P, Holmgren A, Kinnula VL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 2001;7:1750-1757.
37. Tiitto L, Kaarteenaho-Wiik R, Sormunen R, Holmgren A, Paakko P, Soini Y, Kinnula VL. Expression of the thioredoxin system in interstitial lung disease. J Pathol 2003;201:363-370.
38. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003;28:555-562.
39. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163:737-744.
40. Miura T, Okazaki R, Yoshida H, Namba H, Okai H, Kawamura M. Mechanisms of analgesic action of neurotropin on chronic pain in adjuvant-induced arthritic rat: roles of descending noradrenergic and serotonergic systems. J Pharmacol Sci 2005;97:429-436.
41. Isowa N, Yoshimura T, Kosaka S, Liu M, Hitomi S, Yodoi J, Wada H. Human thioredoxin attenuates hypoxia-reoxygenation injury of murine endothelial cells in a thiol-free condition. J Cell Physiol 2000;182:33-40.
42. Iwata S, Hori T, Sato N, Hirota K, Sasada T, Mitsui A, Hirakawa T, Yodoi J. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state. J Immunol 1997;158:3108-3117.
43. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-1060.
44. Kaghad M, Dessarps F, Jacquemin-Sablon H, Caput D, Fradelizi D, Wollman EE. Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. Gene 1994;140:273-278.
45. Kim YC, Masutani H, Yamaguchi Y, Itoh K, Yamamoto M, Yodoi J. Hemin-induced activation of the thioredoxin gene by Nrf2: a differential regulation of the antioxidant responsive element by a switch of its binding factors. J Biol Chem 2001;276:18399-18406.
46. Taniguchi Y, Taniguchi-Ueda Y, Mori K, Yodoi J. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (TRX) gene. Nucleic Acids Res 1996;24:2746-2752.
47. Kondo N, Ishii Y, Kwon YW, Tanito M, Horita H, Nishinaka Y, Nakamura H, Yodoi J. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 2004;172:442-448.